Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial

Patricia J. A. M. Brouwers; Erik van Werkhoven; Harry Bartelink; Alain Fourquet; Claire Lemanski; Judith van Loon; John H. Maduro; Nicola S. Russell; Luc J. E. E. Scheijmans; Dominic A. X. Schinagl; Antonia H. Westenberg; Philip Poortmans; Liesbeth J. Boersma; Young Boost Trial research group

doi:10.1016/j.radonc.2018.06.020

Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial

Patricia J. A. M. Brouwers^*, Erik van Werkhoven, Harry Bartelink, Alain Fourquet, Claire Lemanski, Judith van Loon, John H. Maduro, Nicola S. Russell, Luc J. E. E. Scheijmans, Dominic A. X. Schinagl, Antonia H. Westenberg, Philip Poortmans, Liesbeth J. Boersma, Young Boost Trial research group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: In the Young Boost trial (YBT), breast cancer patients

Methods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT. core, were investigated using a proportional odds model.

Results: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO +/- 65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.

Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO. (C) 2018 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	434-441
Number of pages	8
Journal	Radiotherapy and Oncology
Volume	128
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2018.06.020
Publication status	Published - Sept 2018

Keywords

Breast conserving therapy
Cosmetic outcome
Fibrosis
Young patients
Young boost trial
SIMULTANEOUS INTEGRATED BOOST
INTENSITY-MODULATED RADIOTHERAPY
NO BOOST
RADIATION-THERAPY
TUMOR BED
CONFORMAL RADIOTHERAPY
CONSERVATIVE TREATMENT
RANDOMIZED-TRIALS
EORTC BOOST
FOLLOW-UP

Access to Document

10.1016/j.radonc.2018.06.020

Cite this

Brouwers, P. J. A. M., van Werkhoven, E., Bartelink, H., Fourquet, A., Lemanski, C., van Loon, J., Maduro, J. H., Russell, N. S., Scheijmans, L. J. E. E., Schinagl, D. A. X., Westenberg, A. H., Poortmans, P., Boersma, L. J., & Young Boost Trial research group (2018). Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. Radiotherapy and Oncology, 128(3), 434-441. https://doi.org/10.1016/j.radonc.2018.06.020

@article{0ba132cfd2484b1590f6805752284136,

title = "Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial",

abstract = "Purpose: In the Young Boost trial (YBT), breast cancer patientsMethods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT. core, were investigated using a proportional odds model.Results: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO +/- 65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO. (C) 2018 Elsevier B.V. All rights reserved.",

keywords = "Breast conserving therapy, Cosmetic outcome, Fibrosis, Young patients, Young boost trial, SIMULTANEOUS INTEGRATED BOOST, INTENSITY-MODULATED RADIOTHERAPY, NO BOOST, RADIATION-THERAPY, TUMOR BED, CONFORMAL RADIOTHERAPY, CONSERVATIVE TREATMENT, RANDOMIZED-TRIALS, EORTC BOOST, FOLLOW-UP",

author = "Brouwers, {Patricia J. A. M.} and {van Werkhoven}, Erik and Harry Bartelink and Alain Fourquet and Claire Lemanski and {van Loon}, Judith and Maduro, {John H.} and Russell, {Nicola S.} and Scheijmans, {Luc J. E. E.} and Schinagl, {Dominic A. X.} and Westenberg, {Antonia H.} and Philip Poortmans and Boersma, {Liesbeth J.} and {Young Boost Trial research group}",

year = "2018",

month = sep,

doi = "10.1016/j.radonc.2018.06.020",

language = "English",

volume = "128",

pages = "434--441",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Brouwers, PJAM, van Werkhoven, E, Bartelink, H, Fourquet, A, Lemanski, C, van Loon, J, Maduro, JH, Russell, NS, Scheijmans, LJEE, Schinagl, DAX, Westenberg, AH, Poortmans, P, Boersma, LJ & Young Boost Trial research group 2018, 'Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial', Radiotherapy and Oncology, vol. 128, no. 3, pp. 434-441. https://doi.org/10.1016/j.radonc.2018.06.020

Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. / Brouwers, Patricia J. A. M.; van Werkhoven, Erik; Bartelink, Harry et al.
In: Radiotherapy and Oncology, Vol. 128, No. 3, 09.2018, p. 434-441.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy

T2 - Results of the Young boost trial

AU - Brouwers, Patricia J. A. M.

AU - van Werkhoven, Erik

AU - Bartelink, Harry

AU - Fourquet, Alain

AU - Lemanski, Claire

AU - van Loon, Judith

AU - Maduro, John H.

AU - Russell, Nicola S.

AU - Scheijmans, Luc J. E. E.

AU - Schinagl, Dominic A. X.

AU - Westenberg, Antonia H.

AU - Poortmans, Philip

AU - Boersma, Liesbeth J.

AU - Young Boost Trial research group

PY - 2018/9

Y1 - 2018/9

N2 - Purpose: In the Young Boost trial (YBT), breast cancer patientsMethods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT. core, were investigated using a proportional odds model.Results: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO +/- 65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO. (C) 2018 Elsevier B.V. All rights reserved.

AB - Purpose: In the Young Boost trial (YBT), breast cancer patientsMethods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and four years after treatment. Associations between potential risk factors for worse cosmetic outcome, based on the objective BCCT. core, were investigated using a proportional odds model.Results: At four years, CO was significantly better in the standard boost group for all three scoring methods (satisfied CO +/- 65% vs 55%). A photon boost, high boost dose, poor cosmesis before radiation therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO.Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These results can be used to define strategies aimed at improving CO. (C) 2018 Elsevier B.V. All rights reserved.

KW - Breast conserving therapy

KW - Cosmetic outcome

KW - Fibrosis

KW - Young patients

KW - Young boost trial

KW - SIMULTANEOUS INTEGRATED BOOST

KW - INTENSITY-MODULATED RADIOTHERAPY

KW - NO BOOST

KW - RADIATION-THERAPY

KW - TUMOR BED

KW - CONFORMAL RADIOTHERAPY

KW - CONSERVATIVE TREATMENT

KW - RANDOMIZED-TRIALS

KW - EORTC BOOST

KW - FOLLOW-UP

U2 - 10.1016/j.radonc.2018.06.020

DO - 10.1016/j.radonc.2018.06.020

M3 - Article

C2 - 29980320

SN - 0167-8140

VL - 128

SP - 434

EP - 441

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -

Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this